GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » Cyclically Adjusted Price-to-FCF

Portage Biotech (Portage Biotech) Cyclically Adjusted Price-to-FCF : (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Portage Biotech Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Portage Biotech Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Portage Biotech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Cyclically Adjusted Price-to-FCF Chart

Portage Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Portage Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Portage Biotech's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Portage Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portage Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Cyclically Adjusted Price-to-FCF falls into.



Portage Biotech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Portage Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Portage Biotech's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.164/129.4194*129.4194
=-0.164

Current CPI (Dec. 2023) = 129.4194.

Portage Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.556 99.695 -0.722
201406 -0.211 100.560 -0.272
201409 -0.432 100.428 -0.557
201412 -0.214 99.070 -0.280
201503 -0.490 99.621 -0.637
201506 -0.403 100.684 -0.518
201509 -0.947 100.392 -1.221
201512 -0.563 99.792 -0.730
201603 -0.503 100.470 -0.648
201606 -1.625 101.688 -2.068
201609 -0.436 101.861 -0.554
201612 -0.085 101.863 -0.108
201703 1.218 102.862 1.532
201706 -0.090 103.349 -0.113
201709 -0.089 104.136 -0.111
201712 -0.129 104.011 -0.161
201803 -0.076 105.290 -0.093
201806 -0.065 106.317 -0.079
201809 -0.066 106.507 -0.080
201812 -0.037 105.998 -0.045
201903 -0.035 107.251 -0.042
201906 -0.090 108.070 -0.108
201909 -0.113 108.329 -0.135
201912 -0.059 108.420 -0.070
202003 -0.077 108.902 -0.092
202006 -0.062 108.767 -0.074
202009 -0.161 109.815 -0.190
202012 -0.066 109.897 -0.078
202103 -0.076 111.754 -0.088
202106 -0.129 114.631 -0.146
202109 -0.096 115.734 -0.107
202112 -0.124 117.630 -0.136
202203 -0.169 121.301 -0.180
202206 -0.163 125.017 -0.169
202209 -0.150 125.227 -0.155
202212 -0.159 125.222 -0.164
202303 -0.270 127.348 -0.274
202306 -0.195 128.729 -0.196
202309 0.000 129.860 0.000
202312 -0.164 129.419 -0.164

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Portage Biotech  (NAS:PRTG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Portage Biotech Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Portage Biotech (Portage Biotech) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech (Portage Biotech) Headlines

From GuruFocus